Sacubitril plus valsartan reduces early readmission risk in HF

The risk of readmission within 30 days of heart failure hospitalisation is reduced by a quarter for patients receiving sacubitril/valsartan compared with those receiving enalapril, an analysis of PARADIGM-HF trial data shows.
Source: MedWire News - Category: Consumer Health News Tags: Heart failure Source Type: news